Type 2-diabetes i Danmark

Ugeskrift for Laeger

Volumn 174, Issue 37, 2012, Pages 2132-2138

  Beck Nielsen, Henning ^a   Henriksen, Jan Erik ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PATHWAY; DENMARK; GENETICS; HEALTH CARE DELIVERY; HEALTH SERVICE; HUMAN; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGANIZATION AND MANAGEMENT; PHENOTYPE;

CRITICAL PATHWAYS; DELIVERY OF HEALTH CARE; DENMARK; DIABETES MELLITUS, TYPE 2; HEALTH SERVICES ADMINISTRATION; HUMANS; MASS SCREENING; PHENOTYPE;

EID: 84867591220     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Stovring H, Andersen M, Beck-Nielsen H et al. Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 2003;362:537-8.
2. Carstensen B, Kristensen JK, Ottosen P et al. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 2008;51:2187-96.
3. Maersk M, Belza A, Stodkilde-Jorgensen H et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr 2012;95:283-9.
4. Griffin SJ, Borch-Johnsen K, Davies MJ et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:156-67.
5. Jørgensen T, Glumer C, Borch-Johnsen K. Screening og intervention. Ugeskr Læger 2002;164:2135-9.
6. Glumer C, Jørgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care 2003;26:2335-40.
7. Det Nationale Indikatorprojekt (NIP). http://www.nip.dk (3. maj 2012).
8. Carstensen B, Kristensen JK, Marcussen MM et al. The National Diabetes Register. Scand J Public Health 2011;39(suppl 7):58-61.
9. Forløbsprogram for voksne patienter med type 2-diabetes i Region Syddanmark April 2010: http://www.regionsyddanmark.dk/wm280603 (3. maj 2012).
10. Kronisk sygdom. Patient, sundhedsvæsen og samfund. København: Sundhedsstyrelsen, 2005.
11. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
12. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
13. Soulimane S, Simon D, Shaw J et al. HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R. Diabetes Res Clin Pract 2012;96:392-9.
14. Beck-Nielsen H. Det metaboliske syndrom i daglig klinik. Ugeskr Læger 2010;172:1746-51.
15. Dansk Endokrinologisk Selskab behandlingsvejledning: Behandling og kontrol af type 2 diabetes 2011: http://www.endocrinology.dk/index.php/1-diabetesmellitus/ 1-behandling-af-type-2-diabetes#Valgaffarmakologisk (27. jan 2012).
16. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
17. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55.
18. Beck-Nielsen H, Solomon TPJ, Lauridsen J et al. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: Expected outcome from the DD2-project and two intervention studies. Clin Epidemiol 2012 (i trykken).